Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 61,480 shares of the medical equipment provider’s stock after selling 390 shares during the period. Vontobel Holding Ltd.’s holdings in Intuitive Surgical were worth $20,741,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Liberty Capital Management Inc. lifted its position in Intuitive Surgical by 3.8% in the fourth quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 30 shares during the period. Miracle Mile Advisors LLC lifted its position in Intuitive Surgical by 2.3% in the fourth quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock valued at $485,000 after purchasing an additional 32 shares during the period. Ausdal Financial Partners Inc. lifted its position in Intuitive Surgical by 1.5% in the fourth quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock valued at $739,000 after purchasing an additional 33 shares during the period. Venturi Wealth Management LLC lifted its position in Intuitive Surgical by 10.7% in the fourth quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 33 shares during the period. Finally, Modera Wealth Management LLC lifted its position in Intuitive Surgical by 2.0% in the third quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock valued at $501,000 after purchasing an additional 34 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares of the company’s stock, valued at approximately $43,677.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the completion of the sale, the executive vice president now directly owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the sale, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The disclosure for this sale can be found here. In the last three months, insiders sold 248,418 shares of company stock valued at $95,927,097. Company insiders own 0.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ISRG shares. Piper Sandler raised their price objective on shares of Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research report on Wednesday, January 24th. Royal Bank of Canada lifted their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research report on Wednesday, January 24th. Citigroup lifted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James lifted their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Finally, Mizuho lifted their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $375.70.

Intuitive Surgical Stock Performance

ISRG stock opened at $377.36 on Tuesday. The stock has a market capitalization of $133.76 billion, a P/E ratio of 75.02, a PEG ratio of 5.97 and a beta of 1.36. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The company has a 50 day moving average price of $388.13 and a two-hundred day moving average price of $341.56.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, topping the consensus estimate of $1.48 by $0.12. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. Intuitive Surgical’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.91 EPS. Research analysts forecast that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.